NewAmsterdam Pharma Company N.V. Increase Decrease In Fair Value Measurement Due To Reasonably Possible Decrease In Unobservable Input Recognised In Profit Or Loss Before Tax Entitys Own Equity Instruments
NewAmsterdam Pharma Company N.V. (NAMS) reported Increase Decrease In Fair Value Measurement Due To Reasonably Possible Decrease In Unobservable Input Recognised In Profit Or Loss Before Tax Entitys Own Equity Instruments of -EUR 3.53 million for the 12-month period ending 2022-12-31, per its 20-F/A filed 2024-10-28.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments · last filed 2024-10-28
| Period end | Increase Decrease In Fair Value Measurement Due To Reasonably Possible Decrease In Unobservable Input Recognised In Profit Or Loss Before Tax Entitys Own Equity Instruments 12 month |
|---|---|
| 2022-12-31 | -3.53M EUR 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |